Clinical Trial Search

Primary: Change From Baseline in Trunk Percent Fat at Week 38 — -1.68; 0.37 percent fat — p=<.0001

Primary: Dose Escalation Phase: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 3; 3; 3; 3 Participants

Primary: Marijuana Use Days in Past 90 Days — 35; 45; 27; 41 days

Primary: Number of Participants With Pre-specified Treatment-related Adverse Events — 3; 5; 3 participants

Primary: Mean Arterial Blood Pressure Following High-salt Diet and Low-salt Diet — 83.3; 89.5 mmHg

Primary: Reach-Accept Testing — 47; 41; 41; 45 Participants

Primary: Adherence to Cabenuva Injections — 1; 17; 0; 1 Participants

Primary: Outcome 1: Serial HIV-1 RNA Levels in Breastmilk. — 2.74; 2.03; 1.70; 1.70 Log10 Viral load copies/ml

Primary: CGM Measured Time <70 mg/dL — 1.58; 1.67; 2.57 % time <70 mg/dL

Primary: Change From Baseline in Hemoglobin (Hb) to the Average Over the Primary Evaluation Period (PEP) (Weeks 20 to 26) — -0.07; 0.14; 0.36 Grams per deciliter (g/dL)

Primary: Surrogate Contraceptive Efficacy — 25.86; 0.04; 47.39 sperm per high power field — p=<0.0001

Primary: Conjunctival Redness Assessed Via Digital Photography Over 90 Minutes in the Dry Eye Chamber — 0.33; 0.44 score on a scale

Primary: Pediatric Anxiety Rating Scale — 10.86; 10.96 score on a scale

Primary: Number of Participants Who do Not Engage in Twitter Activities — 246; 226 Participants — p=< 0.0001

Primary: Psychological Morbidity — 10; 10; 5; 5 score on a scale